Navigation Links
Cell Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, May 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences. 

UBS Global Healthcare Conference
Tuesday, May 21, 2013 at 2:30 p.m. Eastern Time in New York, NY

Jefferies 2013 Global Healthcare Conference
Tuesday, June 4, 2013 at 3:00 p.m. Eastern Time in New York, NY

The presentations will also be webcast live and available for replay after the presentation.  The webcast can be accessed at

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at

Media and Investor Contacts:

Cell Therapeutics, Inc.

Monique Greer
T: +1 206.272.4343

Ed Bell
T: +1 206.272.4345

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

T: +39 02 89659700

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
3. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
4. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
5. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
6. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
7. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
8. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
11. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:5/16/2017)... -- Veratad Technologies, LLC ( ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at . 2016 Year Highlights: ...
Breaking Biology News(10 mins):